SOX11 and ovarian carcinoma: Brennan et al. used an in silico transcriptomic screen and evaluated SOX11 expression using immunohistochemistry and automated algorithms in 76 epithelial ovarian cancer cases, hence concluding that SOX11 loss correlates with decreased recurrence-free survival and a more aggressive phenotype [33].